Current report No. 7/2012

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 12 2012 up to and including January 18 2012 the Company bought 1000 own shares representing 0.00076% of the share capital of the Company, to the total value of BGN 2938 on the Bulgarian Stock Exchange. The average price per share was 2.94 BGN.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

Current report No. 8/2012

The Board of Directors of SOPHARMA AD (the “Company”) hereby informs that from January 19 2012 up to and including January 25 2012 the Company bought 500 own shares representing 0.00038% of the share capital of the Company, to the total value of BGN 1450 on the Bulgarian Stock Exchange. The average price per share was 2.90 BGN.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

Sopharma issued its Q4 2011 Individual Financial Report. It is published in the Financial Information Section -> Reports.

SOPHARMA AD (the “Company”) hereby informs that from 20 June 2013 up to and including 26 June 2013 the Company bought 11210 own shares representing 0.008% of the share capital of the Company, to the total value of BGN 35719.22 on the Bulgarian Stock Exchange. The average price per share was BGN 3.19.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4406582, representing 3.34% of the share capital of the Company.

Please be informed that the Annual General Meeting of shareholders of Sopharma AD, held on 21.06.2013 in Sofia, 5 Lachezar Stanchev str., took the following decisions:

SOPHARMA AD (the “Company”) hereby informs that from 13 June 2013 up to and including 19 June 2013 the Company bought 70285 own shares representing 0.053% of the share capital of the Company, to the total value of BGN 219399.15 on the Bulgarian Stock Exchange. The average price per share was BGN 3.12.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4395372, representing 3.33% of the share capital of the Company.

Sopharma AD (the “Company”) hereby notifies all shareholders of the Company, that, as stated in the Invitation, the Annual General Meeting, convened by the Board of Directors for 21 June 2013 at 11:00 will take place for a first year at Sopharma Business Towers, Building B, floor 3, 5 Lachezar Stanchev Str.. The registration begins at 9:30 until 11:00.

SOPHARMA AD (the “Company”) hereby informs that from 6 June 2013 up to and including 12 June 2013 the Company bought 46607 own shares representing 0.035% of the share capital of the Company, to the total value of BGN 143731.48 on the Bulgarian Stock Exchange. The average price per share was BGN 3.08.

The shares have been bought on the basis of the general meeting resolution No. 7 of 23.06.2010.

The total number of own shares after these transactions is 4325087, representing 3.28% of the share capital of the Company.

In an article dated February 4, 2012 under the name “Sopharma of Bulgaria under EU investigation” the issue of New Europe claims that Sopharma is under investigation by the EU institution (name and function is not specified) onsite in Bulgaria in relation to managing to “to supply more than 70% of the medicines required by (state) hospitals and more than 50% of prescribed medicines”. We would like to draw attention to the fact that the claim of such investigation is completely unjustified and is not supported by any evidence.

Sopharma AD (the “Company”) announces that on 4 June 2013 the Company sold 156 000 ordinary registered shares with voting rights of the capital of United Holding Doverie AD. After this transaction, the share of Sopharma AD in the capital of United Holding Doverie AD decreased to 9.90%.